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Urine and serum lactic dehydrogenase, lactic dehydrogenase
isoenzymes, and alkaline phosphatase in the nephrotic syndrome.
Urinary and serum lactic dehydrogenase (LDH), its isoenzymes,
and alkaline phosphatase (AP) activities were determined for
children with known nephrotic syndrome (NS) (N = 31) and for
normal controls (N = 35 for urine, N = 56 for serum). Patients
with NS were grouped as being in relapse, in remission without
prednisone, in remission for greater than 21 days with predni-
sone therapy, or in remission for less than 21 days with predni-
sone therapy. The relapse group had significant elevations of
urinary LDH and AP when compared with each of the other
groups. The highest urinary LDH values were seen in the relapse
group, and the lowest in normal controls. The groups in remis-
sion had intermediate values of urinary LDH, which decreased
as the length of time in remission increased. Although urinary AP
activities were elevated in patients in relapse, they were subnor-
mal in patients in remission greater than 21 days with prednisone
therapy, suggesting membrane stabilization with resultant reduc-
tion in enzyme release into the urinary tract. The urinary and
serum LDH isoenzyme patterns in the relapse group did not
resemble each other, indicating the increased urinary activity
was not due solely to renal clearance of serum enzymes. Serum
LDH was elevated in the relapse group (P < 0.01), but it was not
statistically different in the remission group when compared with
controls. This study demonstrates increased urinary LDH, AP,
and serum LDH activities in patients with the relapsed NS. In
relapsed patients, the different serum and urine LDH isoenzyme
patterns suggest that the urinary activity may be a result of
diseased renal tissue and not a reflection of increased glomerular
filtration. Monitoring the urinary LDH activity may allow for
detecting the continuing disease at a time when other clinical
signs have normalized.
Déhydrogénase lactique du serum de l'urlne, isoenzymes de Ia
LDII et phosphatases alcalines dans le syndrome nephrotique. La
LDH du serum et de l'urine, les isoenzymes de la LDH et Ia
phosphatase alcaline (AP) ont etC dCterminCes chez 31 enfants
atteints de syndrome nCphrotique (NS) et chez des sujets con-
trôles (N = 35 pour l'urine, N = 56pour Ic serum). Les malades
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atteints de NS ont etC groupCs en récidives, remissions sans
prednisone, remissions depuis plus de 21 jours recevant de Ia
prednisone, remissions de moms de 21 jours recevant de Ia
prednisone. Le groupe des rCcidives avait des augmentations
significatives de LDH et AP par comparaison avec chacun des
autres groupes. Les valeurs les plus élevées de LDH urinaire ont
etC observCes dans le groupe des récidives et les plus faibles chez
les normaux. Les groupes en remission avaient des valeurs
intermCdiaires de LDH urinaire, valeurs qui diminuent en mCme
ternps que la durCe de remission s'allonge. Les valeurs d'AP
urinaire Ctaient ClevCes dans les rCcidives, les malades en
remission depuis plus de 21 jours recevant de Ia prednisone
avaient des activitCs d'AP infCrieures a Ia normale, cc qui
suggere Ia stabilisation de Ia membrane avec comme résultat Ia
libCratidn de l'enzyme dans l'appareil urinaire. La repartition des
isoenzymes était diffCrente dans Ic serum et l'urine du groupe en
rCcidive, ce qui indique que l'augmentation d'activitC urinaire
n'Ctait pas seulement due a I'augmentation de Ia clearance rénale
des enzymes. La LDH sCrique Ctait élevée dans les récidives (P
<0,01) mais le groupe en remission n'Ctait pas significativement
different des contrôles. Cette étude démontre une augmentation
de l'activitC urinaire de LDH et AP et de l'activité de Ia LDH
serique chez les malades en rechute de NS. Chez ces malades, Ia
distribution diffCrente des isoenzymes dans Ic serum et l'urine
suggCre que l'augmentation d'activitC urinaire puisse avoir pour
origine le tissu renal altérC et ne reflCte pas l'augmentation de Ia
quantitC filtrCe. La surveillance de l'activitC LDH dans l'urine
peut permettre Ia detection de Ia persistance de Ia maladie a un
moment oü d'autres ClCments sont normalisCs.
Elevations of urinary enzyme activity have been
reported in a variety of disease states [1—10], in
which proteinuria is a frequent, if not constant,
manifestation. Patients with the nephrotic syn-
drome have been studied to determine the urinary
enzyme concentration of alkaline phosphatase
(AP), lactic dehydrogenase (LDH) [1—3, 8, 11], and
its isoenzymes [3, 4, 6]. There is lack of agreement
as to whether the hyperenzymuria found in most
proteinuric states is the result of a generalized
increase in glomerular capillary permeability [2, 121
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or to an increased release from a diseased urinary
tract [6, 10, 121. Few studies have examined coinci-
dent activities of serum and urine LDH, LDH
isoenzymes, and total alkaline phosphatase in pa-
tients with the nephrotic syndrome [13].
The present investigation was undertaken to de-
lineate the source of the hyperenzymuria in patients
with the nephrotic syndrome and to compare the
alterations that occur in both serum and urine
enzyme concentrations in relapse and remission.
Methods
The protocol for this study was approved by the
Medical Center Human Experimentation Commit-
tee, and informed parental consent was obtained for
all participants.
Patients. We selected 30 children (ages, 3.5 to 18
years; 9 females and 21 males) from patients attend-
ing the Pediatric Nephrology Clinic of Duke Uni-
versity. All patients were normotensive and without
any urinary tract symptoms. In 29 patients, the
serum creatinine concentration was in the range of
0.3 to 0.9 mg/dl, and the creatinine clearance was
greater than or equal to 90 mI/mm per 1.73 m2. In
one patient, the serum creatinine was 1.3 rng/dl, and
the creatinine clearance was 80 ml/min per 1.73 m2.
Twenty-three patients had undergone prior renal
biopsy, with the findings, as defined by the Interna-
tional Study of Kidney Disease in Children [14], of
no lesion in 14, mesangial proliferative glomerulo-
nephritis in 7, and focal segmental glomerular scle-
rosis in 2. All patients had a steroid-sensitive ne-
phrotic syndrome with a complete disappearance of
proteinuria within 28 days when treated with
prednisone, 60 mg/rn2 per 24 hr. Criteria for admis-
sion to this study were as follows:
(1) Nephrotic syndrome in relapse. A patient was
considered to be in relapse if, after a period of
remission, he had either 3+ protein by Albustix®
on 3 consecutive daily specimens, or proteinuria on
one occasion accompanied by edema and a serum
albumin concentration of less than 2.5 g/dl.
(2) Nephrotic syndrome in remission. A patient
was considered to be in remission if he had protein-
uria less than 200 mg per 1.73 m2 per day and/or no
urinary protein by Albustix® as determined on 3
consecutive days, no edema, and a serum albumin
greater than 2.5 g/dl. A patient in remission receiv-
ing prednisone was designated as being in steroid
remission and was subgrouped as either greater or
less than 21 days in remission. During each clinic
visit, urinalysis was performed, and any patient was
excluded from the study if a spun urinalysis demon-
strated a positive benzidine, pyuria (greater than 5
WBC per high power field [hpf]) or hematuria
(greater than 5 RBCIhpf). No patient had any signs
or symptoms of urinary tract infection or bacteri-
uria.
Controls. Thirty-five healthy school children
(ages 5 to 12 years) served as normal controls for
the urinary studies. Each had a normal urinalysis,
with spun samples being free of pyuria, bacteriuria,
and hematuria and negative in the benzidine reac-
tion. Fifty-six pediatric clinic patients (ages 1 to
18.5 years) served as normal controls for the serum
enzyme levels. The children were being bled for
routine tests, and no patient had known hepatic,
renal, or central nervous system disease or dysfunc-
tion.
Urine studies. All urine specimens were obtained
by midstream collection after the genitalia were
cleansed. A routine urinalysis was performed with-
in 2 hours after collection, by a dipstick method
(Labstix®) on unspun urine. A lO-ml sample of
urine was centrifuged at x 800g for 10 mm, the
supernate decanted, and a benzidine reaction per-
formed. The sediment was examined microscopi-
cally (magnification, x 400) for WBC and RBC.
All urine samples were assayed for LDH, AP,
and LDH isoenzymes within 48 hours of collection
by using concentrated urine that was first centri-
fuged (within 3 hours), and dialyzed (within 24
hours of collection). A 10-ml sample of spun urine
was dialyzed for 120 mm against running tap water.
The dialysis tubing was pretreated by boiling for 20
mm in 1% EDTA followed by soaking in deionized
water for greater than 24 hours. The retentate was
concentrated approximately 100-fold by vacuum (0
to 4° C) in a collodion concentration bag with a
25,000-dalton cutoff (Schleicher and Schuell Inc.),
with a modification of the method of Amador,
Zimmerman, and Wacker [4, 15]. The residual
concentrate was removed from the collodion bag,
which was then washed with 75 l of 0.9% sodium
chloride. The total volume of the retentate and
washings was adjusted to 200 pi with 0.9% sodium
chloride. Total LDH activity of the concentrated,
dialyzed specimen was assayed according to a
modification of the method of Amador, Dorfman,
and Wacker [16] with a Centrifichem autoanalyzer.
Total alkaline phosphatase activity was assayed
according to a modification of the method of Bow-
ers and McComb [17] with a Beckman TR® autoan-
alyzer. LDH isoenzyme determinations were done
by a modification of the method of Carvajal et a!
[10], with a 1-pi sample at all times.
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Urinary creatinine was measured on refrigerated
(4° C) specimens within 7 to 14 days of collection.
Serum studies. Blood specimens obtained by
venipuncture were allowed to clot at room tempera-
ture and then centrifuged at x 800g for 10 mm. The
serum was removed and refrigerated (4° C) until
assayed (48 to 72 hours). Total LDH activity, total
AP activity, and LDH isoenzyme activity was mea-
sured as described above.
Statistics. The major part of the statistical analy-
sis was directed toward discerning differences and
ordering between the five groups of subjects (nor-
mal, relapse, remission for greater than 21 days on
prednisone, remission for less than 21 days on
prednisone, remission receiving no prednisone)
with respect to urine and serum LDH and AP and
LDH isoenzymes. As the LDH isoenzymes neces-
sarily add up to 100%, for statistical reasons LDH I
was omitted. Because the age distribution was not
similar for the five groups, an adjustment for age
was considered necessary to the analysis. There-
fore, a regression analysis incorporating age as a
covariate was performed for each of the variables of
interest. Because preliminary analyses indicated a
serious departure from normality in most models,
the (natural) log transformation was applied to each
of the variables. There is precedence in the litera-
ture for taking this particular transformation [18);
the residuals from the resulting models did not
appear to violate the normality assumption. We
noticed that the variables U-LDH 4 and U-LDH 5
took on the value zero several times, (natural log of
which is indeterminable), thus creating a high per-
centage of missing values when this transformation
was applied. To remedy this situation, we added 0.1
to U-LDH 4 and U-LDH 5 before transformation.
Duncan's multiple range test, a pairwise compari-
son procedure for discerning differences between
group means, was then applied within the regres-
sion models. This test was used to determine, for
each of the enzymes individually, which groups of
subjects were significantly different from each other
at the 0.05 level.
Results
Patients with known nephrotic syndrome, in re-
lapse and in remission, were studied for serum and
urinary concentrations of AP and LDH and its
isoenzymes, and these enzyme levels were com-
pared with those of normal individuals. Table 1
gives the individual group sample sizes, untrans-
formed group means, and means for the log-trans-
formed variables (in parentheses).
Figure 1 is a graphic representation of the results
of Duncan's procedure. This figure demonstrates
the relative distances between group means (of the
log-transformed variables) for each of the enzymes
studied. It also indicates which groups should be
considered similar; those groups which share a
common underline are not significantly different
from each other at the 0.05 level. For example, for
the variable U-LDH (lu/C), those subjects in re-
lapse have, on the average, the highest values, and
this group is significantly different from the other
four groups. Likewise, the group of patients in
remission less than 21 days can be considered
significantly different from the other four groups.
But, the group of patients in remission greater than
21 days and the group in remission on no steroids
are not significantly different from each other. The
latter group is also similar to the normal group, but
there is a significant difference between the normal
group and the group in remission greater than 21
days.
In general, patients presenting in relapse had
statistically significant elevations of urinary LDH
and AP (P < 0.05) compared with all other patients
and control groups. Urinary enzyme activity was
expressed as international units per gram of creati-
nine (lU/C) rather than per liter because it mini-
mized the variation within the groups. The same
trend to elevated urinary levels was seen, however,
when these enzymes were measured in internation-
al units per liter. Patients in remission (less than 21
days) receiving prednisone were found to have
urinary AP levels that were indistinguishable from
normal control values, but they still had levels of
urinary LDH significantly increased above those
same controls. The highest urinary LDH values
were seen in the relapse group, the lowest in the
normal controls, with remission groups having val-
ues intermediate, correlating with the length of time
in remission. Patients in remission (greater than 21
days) receiving prednisone were found to have
urinary AP levels significantly lower than normal
controls and continued to have suppressed levels
when prednisone was discontinued.
When urinary LDH isonezymes were examined,
we found that U-LDH 4 was significantly increased
in each group when compared with normal controls.
This is of interest as U-LDH 4 is found in large
quantities in kidney tissue [19]. Urinary LDH isoen-
zyme patterns are significantly different from the
same serum LDH isoenzymes. For the relapse
group in particular, a multivariate analysis of differ-
ences in the log-transformed isoenzyme values be-
tween serum and urine was significant (P K 0.02).
Serum studies demonstrated that patients in re-
lapse had a statistically significant elevation in
serum LDH as compared with normals, but the
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Table 1. Urine and serum LDH and AP activity and LDH isoenzymesa
Enzyme Normal"
During
remission and
no steroidsc
During
remission
> 21 days"
During
remission
< 21 days"
During
relapsed
U-LDH, lU/liter 4.65 (1.30) 4.86 (1.40) 3.35 (0.98) 26.66 (3.01) 49.71 (3.73)
U-LDH, lu/c 2.96 (0.89) 3.56 (1.11) 4.94 (1.52) 14.52 (2.42) 23.96 (3.14)
U-AP, lU/liter 2.83 (ti.88) 1.59 (0.19) 0.59 (— .68) 4.03 (1.19) 42.78 (3.79)
U-AP, lU/C
S-LDH, lU/liter
1.79 (0.48)
231 (5.41)
1.09 (— .10)
200* (5.29)
0.92 (— .13)
208 (5.32)
2.29 (0.60)
233 (5.44)
33.24 (3.19)
282* (5.61)
S-AP, lu/liter 277 (5.57) 218* (5.35) 225 (5.33) 179 (5.09) 163* (495)
U-LDH 2, % 26.5 (3.4t) 29.4* (3.35) 33.7 (3.51) 30.3 (3.41) 35.6 (3.57)
U-LDH 3, % 9.8 (2.48) 12.3* (2.43) 12.4 (2.48) 13.9 (2.59) 13.3 (2.57)
U-LDH 4, % 3.0 (— .26) 6.0* (1.60) 4.9 (1.49) 7.7 (1.88) 3.6 (1.25)
U-LDH 5, % 2.9 (— .65) 6.0* (1.47) 2.3 (— .08) 5.0 (1.36) 0.8 (— .93)
S-LDH 2, % 30.0 (3.40) 32.3 (3.47) 32.1 (3.47) 34.2 (3.53) 27.1* (3.30)
S-LDH 3, % 22.0 (3.09) 22.5 (3.11) 20.7 (3.03) 18.7 (2.93) 24.2* (3.18)
S-LDH 4, % 13.3 (2.58) 11.9 (2.47) 11.8 (2.46) 9.7 (2.25) 15.6* (2.73)
S-LDH 5, % 11.3 (2.39) 10.6 (2.35) 9.5 (2.25) 11.5 (2.42) 13.5* (2.56)
a The number in parentheses is the category mean (log transformed) from which Duncan's multiple range test was performed (Fig. 1).
b N = 34 for U-LDH; N = 35, U-AP, U-LDH 4 and 5; N = 30, U-LDH 2; N = 28, U-LDH 3, and N = 55 for all remaining groups.
C N = 10 except where asterisk appears, then N = 9.
N = 6 except where asterisk appears, then N = 8.
same was not true for serum AP. When remission is
attained the elevated levels of serum LDH are no
longer evidenced.
Discussion
• We have determined the blood and urine AP and
LDH activities and LDH isoenzymes in patients
with the nephrotic syndrome. Although hyperenzy-
muria has been reported in patients with urinary
• tract malignancies, ischemic nephropathy, pyelone-
phritis, and cystitis, as well as in those with
nephrotic syndrome, it is generally regarded as a
nonspecific finding [1—10]. Previous studies in pa-
tients with the nephrotic syndrome have been limit-
____________ ed by the small patient numbers, the lack of classifi-
cation as to whether in relapse or remission, and in
having urinary enzyme activity usually being the
single parameter measured. In these studies, we
divided the patients into groups based on whether
the patient was in nephrotic relapse or remission
and whether in remission for greater or less than 21
I T days. Each of the patient groups was compared
with each other and with normal, pediatric-aged
I individuals.
Urinary LDH and AP activity was significantly
increased in patients in relapsed nephrotic syn-
• drome (Fig. 1) when compared with both normal
___________________
controls, patients in remission receiving no medica-
tion, and patients in remission longer than 21 days.
Urinary LDH activity also remains significantly
high in patients in remission for less than 21 days.
Urinary AP activity in patients receiving predni-
sone actually fell to levels significantly lower than
that of normalS controls. A similar decrease to
subnormal levels did not occur with LDH. The
f'Normal —
o Rem, no steroids
• Relapse
A Rem. >21 days
21 da]
U-LDH,/U/C
U'LDH,IU//iter
________
U-AP, /0/liter A 0 Oj
U-AP, lU/C
SLDH
? t ? ILI
'?
-I
S-AP
U-LDH2
U-LDH3
U-LDH4
U-LDH5
S-LDH2
S-LDH3
S.LDH4
0
IL
• 0
• L
.
S-LDH5
Fig. 1. Relative and statistical placement of group means. The
results of Duncan's multiple range test are graphically represent-
ed. For each enzyme studied, the relationship of one group to all
the others is displayed after being scaled so that only the relative
distances between the means (of the transformed variables) are
evident. Those groups that share a common underline were not
found to be significantly different from each other at the 0.05
level.
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explanation for the fall in AP, but not LDH, is not
clear.
Werner et a! [201 previously demonstrated the
value of using LDH and AP values normalized for
the urine creatinine content. Values so corrected
were less variable than measuring the enzyme activ-
ity as a function of the urine volume or the duration
of time elapsed during the total collection period. In
our studies, when LDH values were normalized by
expressing them as LDH per gram of creatinine, it
became evident that patients in remission less than
21 days had values significantly different from all
other groups. These values fell intermediate be-
tween patients in relapse and those in remission
greater than 21 days. Thus, after the onset of
remission, increased urinary LDH persists in the
absence of significant proteinuria, indicating con-
tinuing renal damage not clinically apparent by
presently used criteria.
We have evidence to support the hypothesis that
renal damage is the major component contributing
to hyperenzymuria seen in nephrotic syndrome in
relapse. Significant discrepancies are found in the
percentages of the various isoenzymes present in
serum as compared with those in urine (Table 1).
This would not be anticipated if hyperenzymuria
were the result of increased serum enzymes being
lost into the urine via increased glomerular capillary
permeability as advanced by Crockson [2]. More
likely, altered LDH isoenzyrne patterns seen in
urine are due to LDH release from damaged renal
tissue.
Evaluation of serum enzyme levels revealed that
LDH activity was elevated in patients in relapse.
Among other possibilities, this may be due to
contracted intravascular volume and/or increased
release of LDH from damaged renal tissue. The
elevated serum levels of the LDH 4 isoenzyme,
known to be in significantly high quantities in
human kidney extracts and in patients with renal
infarction [7, 19, 211, would again suggest the latter
choice to be the correct one. Establishment of
steroid-induced remission is accompanied by return
to normal or subnormal levels of serum LDH 4. It is
interesting to note, however, that urinary LDH 4
levels remain elevated not only in patients in re-
lapse, but also in those receiving steroids, as well as
in those in steroid-free remission.
Similar to previous studies by others [1—3, 8, 13],
we have demonstrated the presence of increased
levels of urinary LDH and AP in patients in neph-
rotic syndrome relapse. In addition, we have shown
concomitant increases in serum LDH, but not AP
levels. With induction of remission by steroid ther-
apy, there is a fall in urinary and serum LDH
activity. The urinary LDH activity decreases as the
length of time in remission increases. Further stud-
ies are necessary to determine if a change in LDH
enzyme excretion might be a predictor of subse-
quent nephrotic relapse.
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